Skorpios Trust

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 5, 2025), Skorpios Trust reported 2 stock positions worth $76.3 million. Its top holding was Stoke Therapeutics (STOK) at 99.8% of the portfolio, followed by SS SPDR S&P Biotech ETF (XBI, 0.2%). Compared with Q3 2024, it reduced 1. The biggest sale was Stoke Therapeutics (STOK, shares −22%).

Most Recent 13F
Q3 2025
Location
LIMASSOL, G4
CIK
0001869333
Portfolio Value
$76.3M (Q4 2024)
SEC Filing
0001123292-25-000035 ↗ filed Feb 5, 2025

Holdings Value

0$50.0M$100.0M$150.0M$200.0M Q1 2024: $195.1M Q1 2024 Q2 2024: $146.7M Q2 2024 Q3 2024: $109.6M Q3 2024 Q4 2024: $76.3M $76.3M Q4 2024 Q1 2025: $46.1M Q1 2025 Q2 2025: $37.1M Q2 2025 Q3 2025: $53.2M Q3 2025

Holdings 2 stocks · $76.3M
STOK Stoke Therapeutics Inc. 99.80% 6,906,181 $76.2M Reduce -22.5%
XBI SS SPDR S&P Biotech ETF 0.20% 1,686 $152K No change

Portfolio Sells Q3 2024 → Q4 2024
STOK Stoke Therapeutics Inc. Reduce -22.5% 99.80% −0.05

Portfolio Buys Q3 2024 → Q4 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 2$53.2MSTOK, XBI
Q2 2025 2$37.1MSTOK, XBI
Q1 2025 2$46.1MSTOK, XBI
Q4 2024 2$76.3MSTOK, XBI
Q3 2024 2$109.6MSTOK, XBI
Q2 2024 2$146.7MSTOK, XBI
Q1 2024 2$195.1MSTOK, XBI